Jasper Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Jasper completed acquisition of Kira Pharmaceuticals in July 2026 (all-stock transaction) and simultaneously closed a $132.0M private placement of non-voting convertible preferred stock led by Affinity Asset Advisors and Ikarian Capital. The company advanced vensobafusp alfa Phase 2 renal basket studies (completed IgAN enrollment, opened FSGS and IC-MPGN cohorts) and briquilimab Phase 1/2 study. Cash position stood at $135.3M as of September 30, 2026; Q3 2026 R&D expense was $8.3M and G&A was $6.4M. Company effected 1-for-30 reverse stock split in November 2026, leaving ~1.1M shares outstanding.
Why this rating
Major capital infusion ($132M ≈ 176% of market cap) is trajectory-enabling for clinical-stage biotech; Kira acquisition adds pipeline depth. Offset by warrant settlement ($2.8M), reverse split dilution signal, and large accumulated deficit now $465M.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $13.67 | +10 min · unknown $14.35 ▲ 4.97% | +30 min · unknown $14.16 ▲ 3.58% | +1 hr · unknown $14.16 ▲ 3.58% | +4 hrs · unknown $13.75 ▲ 0.59% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.